Drug-induced disorders of glucose metabolism mechanisms and management

Drug Safety

Volumn 15, Issue 2, 1996, Pages 135-157

  Chan, Juliana C N ^a   Cockram, Clive S ^a   Critchley, Julian A J H ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; CARDIOVASCULAR AGENT; CATECHOLAMINE DERIVATIVE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON; GLUCOSE; GROWTH HORMONE; HORMONE; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; METFORMIN; OCTREOTIDE; PENTAMIDINE; PSYCHOTROPIC AGENT; SEX HORMONE; SOMATOMEDIN; SULFONYLUREA; THEOPHYLLINE; UNINDEXED DRUG;

DIABETES CONTROL; DISEASE PREDISPOSITION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIVER FAILURE; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW;

EID: 0029802059     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615020-00005     Document Type: Review

References (280)

1. Howell SL. Regulation and mechanism of insulin secretion. In: Besser MG, Bodansky HJ, Cudworth AG, editors. Clinical diabetes: an illustrated text. Philadelphia: J B Lippincott, 1988: 2.1-2.8
2. DeFronzo R. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-87
3. Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994; 43: 736-40
4. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-30
5. Luger I. The insulin-antagonistic effect of the counterregulatory hormones. J Intern Med 1991; 229 Suppl. 2: 41-7
6. Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378-89
7. Axelrod J, Reisine TD. Stress hormones: their interaction and regulation. Science 1984; 224: 452-9
8. Holmäng P, Björntorp P. The effects of cortisol on insulin sensitivity in muscle. Acta Physiol Scand 1992; 144: 425-31
9. Critchley JAJH. Ellis P, Henderson CG, et al. The role of the pituitary adrenocortical axis in reflex responses of the adrenal medulla. J Physiol 1982; 323: 533-41
10. Critchley JAJH, MacLean MR, Ungar A. Inhibitory regulation by co-released peptides of catecholamine secretion by the canine adrenal medulla. Br J Clin Pharmacol 1988; 93: 383-6
11. Froesch ER, Zenobi PD, Hussain M. Metabolic and therapeutic effects of insulin-like growth factor I. Horm Res 1994; 42: 66-71
12. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 1989: 163-83
13. Arky RA. Hypoglycemia associated with liver disease and ethanol. Endocrinol Metab Clin North Am 1989; 18: 75-90
14. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989; 18: 103-21
15. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
16. Reichard P, Nilsson, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9
17. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomised prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
18. DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991; 90: 450-9
19. Cryer PE, Fisher JN, Shamoon H. Hypoglycaemia. Diabetes Care 1994; 17: 734-55
20. Hepburn DA, MacLeod KM, Pell AC, et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabetic Med 1993; 10: 231-7
21. Hepburn DA, Patrick AW, Eadington DW, et al. Unawareness of hypoglycaemia in insulin-treated patients: prevalence and relationship to autonomic neuropaths. Diabetic Med 1990; 7: 711-7
22. Schneider SH, Vitug A, Ananthakrishnan R, et al. Impaired adrenergic response to prolonged exercise in type 1 diabetes. Metabolism 1991; 40: 1219-25
23. Liu D, Adamson U, Lins PE, et al. An analysis of the glucagon response to hypoglycaemia in patients with type 1 diabetes and in healthy subjects. Diabetic Med 1993; 10: 246-54
24. Hepburn DA, Patrick AW, Brash HM, et al. Hypoglycaemia unawareness in type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabetic Med 1991; 8: 934-45
25. Egger M, Smith GD, Teuscher AU, et al. Influence of human insulin on symptoms and awareness of hypoglycaemia: a randomised double-blind crossover trial. BMJ 1991; 303: 622-6
26. Lingenfelser T, Overkamp D, Renn W, et al. Different awareness of hypoglycaemia induced by human or purified pork insulin in type I diabetic patients. Diabetes Res Clin Pract 1991; 13: 29-36
27. Meneilly GS, Milberg WP, Tuokko H. Differential effects of human and animal insulin on the responses to hypoglycemia in elderly patients with NIDDM. Diabetes 1995; 44: 272-7
28. Kern W, Lieb K, Kerner W, et al. Differential effects of human and pork insulin-induced hypoglycemia on neuronal functions in humans. Diabetes 1990; 39: 1091-8
29. Dagogo JS, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426-34
30. Caprio S, Napoli R, Sacca L, et al. Impaired stimulation of gluconeogenesis during prolonged hypoglycemia in intensively treated insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1992; 75: 1076-80
31. Davis M, Mellman M, Friedman S, et al. Recovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. Am J Med 1994; 97: 535-42
32. Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37: 1265-76
33. Hoffman RP, Singer GC, Drash AL, et al. Plasma catecholamine responses to hypoglycemia in children and adolescents with IDDM. Diabetes Care 1991; 14: 81-8
34. Liu DT, Adamson UC, Lins PE, et al. Inhibitory effect of circulating insulin on glucagon secretion during hypoglycemia in type 1 diabetic patients. Diabetes Care 1992; 15: 59-65
35. Liu D, Moberg E, Kollind M, et al. A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man. J Clin Endocrinol Metab 1991; 73: 1123-8
36. Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long duration insulin-dependent diabetes. Lancet 1994; 344: 283-7
37. Egger M, Smith GD, Imhoof H, et al. Risk of severe hypoglycaemia in insulin treated diabetic patients transferred to human insulin: a case control study. BMJ 1991; 303: 617-21
38. Jorgensen LN, Dejgaard A, Pramming SK. Human insulin and hypoglycaemia: a literature survey. Diabetic Med 1994; 11: 925-34
39. Patrick AW, Bodmer CW, Tieszen KL, et al. Human insulin and awareness of acute hypoglycemic symptoms in insulin dependent diabetes. Lancet 1991; 338: 528-32
40. Lingenfelser T, Renn W, Plonz C, et al. Catecholamine response during human and pork insulin-induced hypoglycemia in IDDM patients. Diabetes Care 1992; 15: 261-4
41. Lingenfelser T, Pickert A, Pfohl M, et al. Hypothalamic-pituitary activation does not differ during human and porcine insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. Clin Invest 1993; 72: 56-9
42. Ferrer JP, Esmatjes E, Gonzalez CJ, et al. Symptomatic and hormonal hypoglycaemic responses to human and porcine insulin in patients with type 1 diabetes mellitus. Diabetic Med 1992; 9: 522-7
43. Bendtson I, Binder C. Counterregulatory hormonal response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients: a comparison of equimolar amounts of porcine and semisynthetic human insulin. J Intern Med 1991; 229: 293-6
44. Muhlhauser I, Heinemann L, Fritsche E, et al. Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care 1991; 14: 745-9
45. Colagiuri S, Miller JJ, Petocz P. Double-blind crossover comparison of human and porcine insulin in patients reporting lack of hypoglycaemia awareness. Lancet 1992; 339: 1432-5
46. MacLeod KM, Gold AE, Frier BM. A trial of human and porcine insulin in Type 1 diabetic patients. Diabet Med 1995; 12: 134-41
47. Heine RJ, van der Heyden EA, van der Veen EA. Responses to human and procine insulin in healthy subjects. Lancet 1989; 11: 946-9
48. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45
49. Jennings AM, Wislon RM, Ward JD. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemic agents. Diabetes Care 1989; 12: 203-8
50. Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Ageing 1991; 20: 404-6
51. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-10
52. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. BMJ 1988; 246: 949-50
53. Sugarman JR. Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1991; 14: 139-47
54. Chan TYK, Chan JCN, Tomlinson B, et al. Adverse reactions to drugs as a cause of admission to a general teaching hospital in Hung Kong. Drug Saf 1992; 7: 235-40
55. Chan TYK, Chan JCN, Critchley J AJH. Severe hypoglycaemia in Chinese patients with non-insulin-dependent diabetes treated with insulin or sulphonylureas. Pharmacoepidemiol Drug Saf 1992; 1: 207-11
56. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994; 8: 201-3
57. Tessier D, Dawson K, Tetrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11: 974-80
58. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
59. Asplund K, Wiholm BE, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med 1991; 8: 726-31
60. Huminer D, Dux S, Rosenfeld JB, et al. Inadvertent sulfonylurea-induced hypoglcemia: a dangerous, but preventable condition. Ann Intern Med 1989; 149: 1890-2
61. Sledge ED, Broadstone VL. Hypoglycemia due to a pharmacy dispensing error. South Med J 1993; 86: 1272-3
62. Chan TYK, Chan JCN, Choi SS, et al. Recurrent glibenclamide-induced hypoglycemia: the importance of obtaining a comprehensive medication history. Ann Pharmacother 1994; 28: 119-20
63. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents. Drugs 1981; 22: 295-320
64. Feely J, Peden N. Enhanced sulfunylurea-induced hypoglycaemia with cimetidine. Br J Clin Pharmacol 1983; 16: 607P
65. MacWalter RS, El Debani AH, Feely J, et al. Potentiation by ranitidine of the hypoglycaemic response to glypizide in diabetic patients. Br J Clin Pharmacol 1985; 19: 121P-2P
66. Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycemia and ranitidine. Ann Int Med 1987; 107: 261-2
67. Shrivastava RK, Edwards D. Hypoglycemia associated with imipramine. Biol Psychiatry 1983; 8: 1509-10
68. True BL, Perry PL, Burns HA. Profound hypoglycaemia with the addition of a tricyclic antidepressant to maintenance sulphonylurea therapy. Am J Psychiatry 1987; 144: 1220-1
69. Bailey CJ. Hypoglycaemic, antihyperglycaemic and antidiabetic drugs. Diabet Med 1992; 9: 482-3
70. Bell DSH. Alcohol and NIDDM patients. Diabetes Care 1996; 19; 509-13
71. Berman JD, Cook DM, Buchman M, et al. Diminished adrenocorticotropin response to insulin-induced hypoglycemia in nondepressed, actively drinking male alcoholics. J Clin Endocrinol Metab 1990; 71: 712-7
72. Avogaro A, Beltramello P, Gnudi L, et al. Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients: evidence for a critical role of free fatty acids. Diabetes 1993; 42: 1626-34
73. Christiansen C, Thomsen C, Rasmussen O, et al. Acute effects of graded alcohol intake on glucose, insulin and free fatty acid levels in non-insulin-dependent diabetic subjects. Eur J Clin Nutr 1993; 47: 648-52
74. Critchley JAJH, Proudfoot AT, Boyd SG, et al. Deaths and paradoxes after intentional insulin overdosage. BMJ 1984; 289: 225
75. Vogel C, Caraccio T, Mofenson H, et al. Alcohol intoxication in young children. J Toxicol Clin Toxicol 1995; 33: 25-33
76. Yang CC, Yang LY, Deng JF. Hypoglycemia following ethanol ingestion in children: report of a case. J Formos Med Assoc 1995; 94: 267-70
77. Hornfeldt CS. A report of acute ethanol poisoning in a child: mouthwash versus cologne, perfume and after-shave. J Toxicol Clin Toxicol 1992; 30: 115-21
78. Diwan PV, Sastry MS, Satyanarayana NV. Potentiation of hypoglycmic response of glibenclamide by piroxicam in rats and humans. Indian J Exp Biol 1992; 30: 317-9
79. Giugliano D, Ceriello A, Saccomanno E, et al. Effects of salicylate, tolbutamide and prostaglandin E2 on insulin responses to glucose in non-insulin-dependent diabetes. J Clin Endocrinol Metab 1985; 61: 160-6
80. Bratusch-Marrain PR, Vierhapper H, Komjati M, et al. Acetylsalicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic men. Diabetologia 1985; 28: 671-6
81. Raschke R, Arnold CP, Richeson R, et al. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151: 591-3
82. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
83. Yudkin JS. Hypertension and non-insulin-dependent diabetes. BMJ 1991; 303: 730-2
84. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 40: 203-9
85. Klarr JM, Bhatt MV, Donn SM. Neonatal adrenergic blockade following single dose maternal labetalol administration. Am J Perinatol 1994; 11: 91-3
86. Holm G, Herlitz J, Smith I. Severe hypoglycaemia during physical exercise and treatment with beta-blockers. BMJ 1981; 282: 1360
87. Kerr D, MacDonald IA, Heller SR, et al. Beta-adrenoceptor blockade and hypoglycaemia: a randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990; 29: 685-93
88. Angelo-Nielson K. Timolol topically and diabetes mellitus. JAMA 1980; 244: 2263
89. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
90. Herings RMC, de Boer A, Stricker BHC, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195-7
91. Morris AD, Donnelly R. Angiotensin II: an insulin-sensitizing vasoactive hormone? J Clin Endocrinol Metab 1996; 81: 1303-6
92. Jauch KW, Hartl W, Guenther B, et al. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987; 17: 448-54
93. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2: 581-4
94. Madsen BK, Holmer P, Ibsen H, et al. The influence of caplopril on the epinephrine response to insulin-induced hypoglycemia in humans: the interaction between the renin-angiotensin system and the sympathetic nervous system. Am J Hypertens 1992; 5 (6 Pt 1): 361-5
95. Shionoiri H, Gotoh E, Ito T, et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensive: a multicenter prospective study. Am J Med Sci 1994; 307 Suppl. 1: S91-5
96. Lund-Johnson P, Hjermann I, Iversen BM, et al. Selective alpha-1 inhibitors: first or second-line antihypertensive agents? Cardiology 1993; 83: 150-9
97. Smith RC, Sullivan M, Geller J. Inadequate adrenergic response to disopyramide-induced hypoglycemia. Ann Pharmacother 1992; 26: 490-1
98. Cacoub P, Deray G, Baumelou A, et al. Disopyramide-induced hypoglycaemia case report and reveiw of the literature. Fundam Clin Pharmacol 1989; 3: 527-35
99. Stapleton JT, Gilman MW. Hypoglycaemic coma due to disopyramide toxicity [letter]. South Med J 1983; 76: 1453
100. Jeundel C, Preiss MA, Pierson H, et al. Hypoglycaemia induced by cibenzoline. Lancet 1988; I: 1232-3
101. Hilleman DE, Mohiuddin SM, Ahmed TS, et al. Cibenzoline-induced hypoglycaemia. Drug Intell Clin Pharm 1987; 21: 38-40
102. Cachot BA, Bezier M, Cherrier JF, et al. Cibenzoline and hypoglycemia [letter]. Lancet 1988; II: 280
103. Randle PJ, Hales CN, Garland PB, et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; II: 785-9
104. Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol 1994; 5: 166-74
105. Saha AK. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 1994; 267: E95-F101
106. Donnelly R, Morris AD. Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism. Br J Clin Pharmacol 1994; 37: 311-20
107. Ahmad S. Gemfibrozil: interaction with glyburide [letter]. South Med J 1991; 84: 102
108. Brazy JE, Pupkin MJ. Effects of maternal isoxsuprine administration on preterm infants. J Paediatr 1979; 94: 444-8
109. Musci MNJ, Abbasi S, Otis C, et al. Prolonged fetal ritodrine exposure and immediate neonatal outcome. J Perinatol 1988; 8: 27-32
110. Caldwell G, Scougall I, Boddy K, et al. Fasting hyperinsulinaemic hypoglycemia after ritodrine therapy for premature labour. Obstet Gynaecol 1987; 70: 478-80
111. Wasserman D, Amitai Y. Hypoglycemia following albuterol overdose in a child. Am J Emerg Med 1992; 10: 556-7
112. Krentz AJ, Boyle PJ, MacDonald LM, et a.l Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994; 43: 24-31
113. Lamberts SWJ, Uitterlinden P, Verschoor L, et al. Long term treatment of acromegaly with the somatostatin analogue SM201-995. N Engl J Med 1985; 313: 1576-80
114. Stehouwer CD, Lems WF, Fischer HR, et al. Aggravation of hypoglycaemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol 1989; 21: 34-40
115. Popvic V, Nesovic M, Micic D. Hypoglycaemia in acromegalic patients with long acting somatostatin analogue (SMS 201-995). Horm Metab Res 1989; 21: 282-4
116. Brunner JE, Kruger DF, Basha MA, et al. Hyooglycaemia after administration of somotostatin analog (SMS 201-995) in metastatic carcinoid. Henry Ford Hosp Med J 1990; 37: 60-2
117. Krentz AJ, Boyle PJ, Justice KM, et al. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care 1993; 16: 184-6
118. Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76: 752-6
119. Phillips RE, Warrell DA, Looarcesuwan S. Effectiveness of SMS 201-995, a synthetic long-acting somatoslatin analogue in treatment of quinine-induced hyperinsulinaemia. Lancet 1986; I: 713-15
120. Phillips RE, Looarcesuwan S, Molyneux ME, et al. Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria: treatment with Sandostatin. Q J Med 1993; 86: 233-40
121. Jerôme B, Bluet-Pajot MT, Epelbaum J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995; 132: 12-24
122. Morgan JM, Saris SD, Capuzzi DM, et al. Hypoglycemic and insulin response to a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) in healthy males. J Clin Pharmacol 1993; 33: 366-72
123. Zenobi PD, Holzmann P, Glatz Y, et al. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 1993; 36: 465-9
124. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-41
125. White NJ, Warrell DA, Chanthavanich P. Severe hypoglycaemia and hyperinsulinaemia in falciparum malaria. N Engl J Med 1983; 309: 61-6
126. Krishna S, Waller DW, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994; 88: 67-73
127. Assan R, Perronne C, Chotard L, et al. Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. Diabet Metab 1995; 21: 54-8
128. Okitolonda W, Delacollette C, Malengreau M, et al. High incidence of hypoglycemia in African patients treated with intravenous quinine for severe malaria. BMJ 1987; 295: 716-18
129. Looareesuwan S, Phillips RE, White NJ. Quinine and severe falciparum malaria in late pregnancy. Lancet 1985; II: 4-8
130. Phillips RE, Looareesuwan S, White NJ. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. BMJ 1986; 29: 1391-21
131. White NJ, Miller KD, Marsh K. Does chloroquine cause hypoglycaemia in the absence of clinical malaria. Lancet 1987; II: 281-2
132. Abu-Shakra M, Lee P. Hypoglycemia: an unusual adverse reaction to chloroquine [letter]. Clin Exp Rheumatol 1994; 12: 95
133. Bamber MG, Redpath A. Chloroquine and hypoglycaemia [letler]. Lancet 1987; I: 1211
134. Dyer JR, Davis TM, Giele C, et al. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br J Clin Pharmacol 1994; 38: 205-12
135. Herchline TE, Plouffe JF, Para MF. Diabetes mellitus presenting with ketoacidosis following pentamidine therapy in patients with acquired immunodeficiency syndrome. J Infect 1991; 22: 41-4
136. Sharpe SM. Pentamidine and hypoglycaemia [letter]. Ann Intern Med 1983; 99: 128
137. Salmeron S, Petitprez P, Katalama C. Pentamidine and pancreatitis. Ann Intern Med 1986; 105: 140-1
138. Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycaemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther 1986; 39: 271-5
139. Perronne C, Bricaire F, Leport C, et al. Hypoglycaemia and diabetes mellitus following parenteral pentamidine mesylate treatment in AIDS patients. Diabet Med 1990; 7: 585-9
140. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis: determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995; 18: 47-55
141. Karboski JA, Godley PJ. Inhaled pentamidine and hypoglycemia [letter]. Ann Intern Med 1988; 108: 490
142. Poretsky L, Moses AC. Hypoglycemia associated with trimethoprim/sulphamethoxazole therapy. Diabetes Care 1984; 7: 508-9
143. Schattner A, Rimon E, Green L, et al. Hypoglycaemia induced by cotrimoxazole in AIDS [letter]. BMJ 1988; 297: 742
144. Johnson JA, Kappel JE, Sharif MN. Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient. Ann Pharmacother 1993; 27: 304-6
145. Huntsinger NJ. Hypoglycaemic effect of lithium. Biol Psychiatry 1987; 22: 798-9
146. Rigas JR, Tong WP, Kris MG, et al. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res 1992; 52: 6619-23
147. Rigas JR, Francis PA, Miller VA, et al. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 1995; 35: 483-8
148. Bichel T, Canivet JL, Damas P, et al. Malignant hyperthermia and severe hypoglycemia after reexposure to halothane. Acta Anaesthesiol Belg 1994; 45: 23-7
149. Schneider M. Fatal hepatic necrosis following cardiac surgery and enflurane anaesthesia. Anaesth Intensive Care 1995; 23: 225-7
150. Rowland MJ, Bransome EJ, Hendry LB. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted? J Clin Pharmacol 1994; 34: 80-5
151. Yao K, Uchigata Y, Kyono H, et al. Human insulin-specific immunoglobulin G antibody and hypoglycemic attacks after the injection of gold thioglucose. J Endocrinol Invest 1992; 15: 43-7
152. Singh B, Gupta S, Minocha SK, et al. Hypoglycaemia in aluminium phosphide poisoning. J Assoc Physicians India 1994; 42: 663
153. Patial RK, Bansal SK, Kashyap S, et al. Hypoglycaemia following zinc phosphide poisoning. J Assoc Physicians India 1990; 38: 306-7
154. Zogno MG, Tolfo L, Draghi E. Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics. Ann Pharmacother 1994; 28: 406
155. Otsuka M, Akiba T, Okita Y, et al. Lactic acidosis with hypoglycemia and hyperammonemia observed in two uremic patients during calcium hopantenate treatment. Jpn J Med 1990; 29: 324-8
156. Almirall J, Montoliu J, Torras A, et al. Propoxyphene-induced hypoglycaemia. Nephron 1989; 53: 273-5
157. Binder C, Bendtson I. Endocrine emergencies: hypoglycaemia. Baillieres Clin Endocrinol Metab 1992; 6: 23-39
158. Georgakopoulos K, Katsilambros N, Fragaki M, et al. Recovery from insulin-induced hypoglycemia alter saccharose or glucose administration. Clin Physiol Biochem 1990; 8: 267-72
159. Soltesz G. Hypoglycaemia in the diabetic child. Baillieres Clin Endocrinol Metab 1993; 7: 741-55
160. Slama G, Alamowitch C, Desplanque N, et al. Anew non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon. Diabetologia 1990; 33: 671-4
161. Rosenfalck AM, Bendtson I, Jorgensen S, et al. Nasal glucagon in the treatment of hypoglycaemia in type I (insulin-dependent) diabetic patients. Diabetes Res Clin Pract 1992; 17: 43-50
162. Hvidberg A, Rasmussen MH, Christensen NJ, et al. Theophylline enhances glucose recovery after hypoglycemia in healthy man and in type I diabetic patients. Metabolism 1994; 43: 776-81
163. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101
164. Walker ED. Hyperglycemia: a complication of chemotherapy in children. Cancer Nurs 1988; 11: 18-22
165. Weissman DE, Dufer D, Vogel V, et al. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987; 5: 125-8
166. Roth D, Milgrom M, Esquenazi V, et al. Posttransplant hyperglycemia: increased incidence in cyclosporin-treated renal allograft recipients. Transplantation 1989; 47: 278-81
167. Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics 1990; 86: 722-7
168. Spear ML, Reeves G, Pearlman SA. Diabetic ketoacidosis after steroid administration for bronchopulmonary dysplasia: a case report. J Perinatol 1993; 13: 232-4
169. Feuerstein BL, Lebowitz MR, Blumenthal SA, et al. Severe hyperkalemia in two patients with diabetes after cosyntropin administration. J Diabetes Complications 1992; 6: 203-6
170. Bruno A, Carucci P, Cassader M, et al. Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man. Eur J Clin Pharmacol 1994; 46: 411-5
171. Cerqueti PM, Sacca SC, Allegri P, et al. Deflazacort in the treatment of uveitis: a comparative study versus prednisone. Allergol Immunopathol (Madr) 1993; 21: 107-10
172. Ferrari A, Pasqualetti D, Del BP, et al. Prednisone versus deflazacort in the treatment of autoimmune thrombocytopenic purpura: evaluation of clinical response and immunological modifications. Haematologica 1991; 76: 342-5
173. Perlman JA, Russell-Briefel R, Ezzati T, et al. Oral glucose tolerance and the potency of contraceptive progestins. J Chronic Dis 1985; 38: 857-64
174. Eschwége E, Fontbonne A, Simon D, et al. Oral contraceptives, insulin resistance and ischaemic vascular disease. Int J Gynaecol Obstet 1991; 31: 263-9
175. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies of 171 women ingesting Premarin, mestranol and ethinylestradiol for six months. Am J Obstet Gynecol 1981; 114: 378-92
176. Spellacy WN. Carbohydrate metabolism during treatment with oestrogen, progestogen and low-dose oral contraceptives. Am J Obstet Gynaecol 1982; 142: 732-4
177. Bottino JC, Tashima CK. Medroxyprogesterone acetate and diabetes mellitus. Ann Intern Med 1976; 84: 341-2
178. Panwalker AP. Hyperglycemia induced by megestrol acetate [letter]. Ann Intern Med 1992; 116: 878
179. De Pirro R, Forte F, Bertoli A, et al. Changes in insulin receptors during the menstrual cycle in normal women. J Clin Endocrinol Metab 1981; 52: 29-33
180. De Pirro R, Forte F, Bertoli A, et al. Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab 1981; 52: 29-33
181. Munck A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms and physiological significance. Perspect Biol Med 1971; 14: 265-9
182. Skouby SO, Molsted-Pedersen L, Petersen KR. Contraception tor women with diabetes: an update. Ballieres Clin Obstet Gynaecol 1991; 5: 493-503
183. van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynaecol 1987; 156: 918-22
184. Molsted-Pederson L, Skouby SO, P D. Preconception counselling and contraception after gestational diabetes. Diabetes Care 1991; 40 Suppl. 2: 147-50
185. Miccoli R, Orlandi MC, Fruzzetti F. Metabolic effects of three new low dose pills: a six month experience. Contraception 1989; 39: 643-52
186. Kung AWC, Ma JTC, Wong VCW. Glucose and lipid metabolism with triphasic oral contraceptives in women with history of gestational diabetes. Contraception 1989; 35: 257-69
187. Kamau RK, Maina FW, Kigondu C, et al. The effect of low-oestrogen combined pill, progestogen-only pill and medroxyprogesterone acetate on oral glucose tolerance test. East Afr Med J 1990; 67; 550-5
188. Mathews KA, Meilahn E, Lewis MPM. Menopause and risk factors for CHD. N Engl J Med 1989; 321: 641-6
189. Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. BMJ 1992; 305: 1403-8
190. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309-17
191. Rosenbaum M, Gertner JM, Leibel RL. Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH deficient children. J Clin Endocrinol Metab 1989; 69: 1274-81
192. De Boer H, Blok G-J, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Rev 1995; 16: 63-86
193. Ho KK, Hoffman DM. Aging and growth hormone. Horm Res 1993; 40: 80-6
194. Garg AK. Hyperglycemia during replacement growth hormone therapy [leller]. J Pediatr 1994; 125: 329
195. Lehmann S, Cerra FB. Growth hormone and nutritional support: adverse metabolic effects. Nutr Clin Pract 1992; 7: 27-30
196. Ingemarsson I, Arulkumaran S, Kottegoda SR. Complication of beta-mimetic therapy in preterm labour. Aust N Z J Obstet Gynaecol 1985; 25: 182-9
197. Adam K, Ou CN, Cotton DB. Combined effect of terbutaline and betamethasone on glucose homeostasis in preterm labor. Fetal Diagn Ther 1993; 8: 187-94
198. Gündogdu AS, Brown PM, Juul S, et al. Comparison of hormonal and metabolic effects of salbutamol infusion in normal subjects and insulin-requiring diabetics. Lancet 1979; II: 1317-21
199. Spellacy WN, Cruz AC, Buhi WC, et al. The acute effects of ritodrine infusion on maternal metabolism: measurements of levels of glucose, insulin, glucagon, triglycerides, cholesterol, placental lactogen and chorionic gonadotrophin. Am J Obstet Gynecol 1978; 131: 637-42
200. Kirkpatrick C, Quenon M, Desir D. Blood anions and electrolytes during ritodrine infusion in preterm labour. Am J Obstet Gynecol 1980; 138: 523-7
201. Leslie D, Coats PM. Salbutamol-induced diabetic ketoacidosis [letter]. BMJ 1977; II: 768
202. Huupponen R, Pihlajamäki K. Effect of blood glucose level on the metabolic response of intravenous salbutamol. Int J Clin Pharmacol Ther Toxicol 1986; 24: 374-6
203. Dawson KP, Penna AC, Manglick P. Acute asthma, salbutamol and hyperglycaemia. Acta Paediatr 1995; 84: 305-7
204. MacRury S, Neilson R, Goodwin K. Benylin dependence, metabolic acidosis and hyperglycemia. Postgrad Med J 1987; 63: 587-8
205. Meechan JG, Welbury RR. Metabolic responses to oral surgery under local anesthesia and sedation with intravenous midazolam: the effects of two different local anesthetics. Anesth Prog 1993; 39: 9-12
206. Karch SB. High-dose epinephrine. Am J Emerg Med 1993; 11: 423-6
207. Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med 1990; 86: 567-76
208. Hagley MT, Traeger SM, Schuckman H. Pronounced metabolic response to modest theophylline overdose. Ann Pharmacother 1994; 28: 195-6
209. Shannon M. Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication. J Toxicol Clin Toxicol 1994; 32: 41-7
210. Shannon M, Lovejoy FJ. Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children. J Pediatr 1992; 121: 125-30
211. Shannon M, Lovejoy FHJ. The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Arch Intern Med 1990; 150: 2045-8
212. Skarfors ET, Lithell HO, Selinus I, et al. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298: 1147-52
213. Bengtsson C, Blohme G, Lapidus L, et al. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of
214. Lewis PJ, Kohner EM, Petrie A, et al. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976; I: 564-6
215. Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993; 118: 273-8
216. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32: 106-11
217. Knauf H. The role of low-dose diuretics in essential hypertension. J Cardiovasc Pharmacol 1993; 22 Suppl. 6: S1-7
218. Ferrari P, Rosman J, Weidmann P. Amihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991; 67: 26B-35B
219. Roux P, Courtois H. Blood sugar regulation during treatment with indapamide in hypertensive diabetics. Postgrad Med J 1981; 57 Suppl. 2: 70-2
220. Osei K, Holland G, Falko JM. Indapamide: effects on apoproteins, lipoproteins and glucoregulation in ambulatory diabetic patients. Ann Intern Med 1986; 146: 1973-3
221. Fonseca V, Phear DN. Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diuretics. BMJ 1982; 284: 36-7
222. Curtis J, Horrigan F, Ahearn D. Chlorthalidone-induced hyperosmolar hyperglycaemic non-ketotic coma. JAMA 1972; 220: 1592-3
223. Rowe P, Mather HG. Hyperosmolar non-ketotic diabete mellitus associated with metolazone. BMJ 1985; 291: 25-6
224. Hall S. Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diuretics [letter]. BMJ 1982; 284: 665
225. Tasker PW, Mitchell-Heggs PF. Non-ketotic diabetic precoma associated with high dose frusemide therapy. BMJ 1976; 1: 262-7
226. Wicklmayr M, Rett K, Deitze G, et al. Effects of beta-blocking agents on insulin secretion and glucose disposal. Horm Metab Res 1990; 22 Suppl.: 29-33
227. Podolsky S, Pattavina CG. Hyperosmolar non-ketotic diabetic coma: a complication of propranolol therapy. Metabolism 1973; 22: 685-93
228. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985; I: 123-6
229. Josselson J, Sadler JH. Nephrotic range proteinuria and hyperglycemia associated with clonidine therapy. Am J Med 1986; 80: 545-6
230. Tse WY, Kendall M. Is there a role for beta-Mockers in hypertensive diabetic patients? Diabet Med 1994; 11: 137-44
231. Trost BN. Glucose metabolism and calcium antagonists. Horm Metab Res 1990; 22 Suppl.: 48-56
232. Chan JCN, Yeung VTF, Leung DHY, et al. The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM. Diabetes Care 1994; 17: 859-62
233. Ahmad S. Nicardipine-induced hyperglycemia [letter]. Am Fam Physician 1992; 45: 449
234. Sharma SN, Iyengar SS, Hegde KP. Nifedipine-induced hyperglycaemia. J Assoc Physicians India 1990; 38: 673-4
235. Heyman SN. Verapamil intoxication and hyperglycaemia [letter]. J Emerg Med 1989; 7: 407
236. Roth A, Miller HI, Belhassen B, et al. Slow release verapamil and hyperglycemic metabolic acidosis. Ann Intern Med 1989; 110: 171-2
237. Enyeart JL, Price WA, Hoffman DA, et al. Profound hyperglycemia and metabolic acidosis alter verapamil overdose. J Am Coll Cardiol 1983; 2: 1228-31
238. Chan JCN, Cockram CS. Drug-induced disturbances of carbohydrate metabolism. Adverse Drug React Toxicol Rev 1991; 10: 1-29
239. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt sensitive patients. Am J Cardiol 1988; 61: 53H-9H
240. Mimouni BA, Mimouni M. Clonidine-induced hyperglycemia in a young diabetic girl [letter]. Ann Pharmacother 1993; 27: 980
241. Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia [letter]? BMJ 1984; 288: 285
242. Lakhdar AA, Farish E, Dunn FG, et al. Amiodarone therapy and glucose intolerance: a prospective trial. Eur J Clin Pharmacol 1988; 34: 651-2
243. Winter WE, Funahashi M, Koons J. Encainide-induced diabetes: analysis of islet cell function. Res Commun Chem Pathol Pharmacol 1992; 76: 259-68
244. Salerno DM, Fifield J, Krejci J, et al. Encainide-induced hyperglycaemia. Am J Med 1988; 84: 39-44
245. Zumoff B, Hellman L. Aggravation of diabetic hyperglycemia by chlordiazepoxide. JAMA 1977; 237: 1960-1
246. Tollefson G, Lesar T. Non-ketotic hyperglycemia associated with loxapine and amoxapine: case report. J Clin Psychiatry 1983; 44: 347-8
247. Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatr 1964; 5: 181-98
248. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994; 151: 1395
249. Marley J, Rohan A. Mianserin-induced hyperglycaemia. Lancet 1993; 342; 1430-1
250. Guigliano D, Ceriello A, di Pinto P, et al. Impaired insulin secretion in human diabetes mellitus: the effect of naloxone-induced opiate receptor blockade. Diabetes 1982; 31: 367-70
251. Olsen GD. Potential mechanism of cocaine-induced developmental neurotoxicity: a mini-review. Neurotoxicology 1995; 16: 159-67
252. Leson CK, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. J Toxicol Clin Toxicol 1988; 26: 407-15
253. Craig J, Abu-Saleh M, Smith B, et al. Diabetes mellitus in patients on lithium [letter]. Lancet 1977; II: 1028
254. Waziri R, Nelson J. Lithium in diabetes mellitus: a paradoxical response. J Clin Psychiatry 1978; 39: 623-5
255. Vendesborg PB. Lithium treatment and glucose tolerance in manic melancholic patients. Acta Psychiatr Scand 1979; 59: 306-16
256. Lee RV, Jampol LM, Brown WV. Nephrogenic diabetes insipidus and lithium intoxication: complications of lithium carbonate therapy. N Engl J Med 1971; 284: 93-4
257. Martinez-Maldonaldo M, Terrell J. Lithium carbonate-induced nephrogenic diabetes insipidus and glucose intolerance [letter]. Arch Intern Med 1973; 132: 881
258. Singer J, Rotenberg D. Mechanisms of lithium action. N Engl J Med 1973; 289: 254-60
259. Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia. J Med 1994; 25: 219-29
260. Wang YJ, Chu HY, Shu SG, et al. Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: report of three cases. Chung Hua I Hsueh Tsa Chih (Taipei) 1993; 51: 457-61
261. Iyer RS, Rao SR, Pai S, et al. L-asparaginase related hyperglycemia. Indian J Cancer 1993; 30: 72-6
262. Sylvester RK, Lobell M, Ogden W, et al. Homoharringtonine-induced hyperglycemia. J Clin Oncol 1989; 7: 392-5
263. Weber J, Gunn H, Yang J, et al. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 1994; 15: 292-302
264. Krentz AJ, Dmitrewski J, Mayer D, et al. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 948-9
265. Takahara S, Kokudo Y, Kameoka H, et al. Monitoring of FK 506 blood levels in kidney transplant recipients. Transplant Proc 1994; 26: 2106-8
266. Tabasco MJ, Mieles L, Carroll P, et al. Insulin requirements alter liver transplantation and FK-506 immunosuppression. Transplantation 1993; 56; 862-7
267. Patel SR, Kvols LK, Rubin J, et al. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs 1991; 9; 53-7
268. Bouvet E, Casalino E, Prevost MH, et al. Fatal case of 2,3-dideoxyinosine-associated pancreatitis [letter]. Lancet 1990; 336: 1515
269. Munshi MN, Martin RE, Fonseca VA. Hyperosmolar non-ketotic diabetic syndrome following treatment of human immunodeficiency virus infection with didanosine. Diabetes Care 1994; 17: 316-7
270. Amar D, Shamoon H, Lazar EJ, et al. Acute hyperglycaemic effect of anaesthetic induction with thiopentonc. Ada Anaesthesiol Scand 1993; 37: 571-4
271. al-Rubeaan K, Ryan EA. Phenytoin-induced insulin insensitivity. Diabet Med 1991; 8: 968-70
272. Fariss BL, Lutcher CL. Diphenylhydantoin-induced hyperglycaemia and impaired insulin release: effect of dosage. Diabetes 1971; 20: 177-81
273. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993; 153: 2050-2
274. Blanco-Coronado JL, Repetto M, Ginestal RJ, et al. Acute intoxication by endosulfan. J Toxicol Clin Toxicol 1992; 30: 575-83
275. Oakley DE, Ellis PP. Glycerol and hyperosmolar nonketotic coma. Am J Ophthalmol 1976; 81: 469-72
276. Sears ES. Nonketotic hyperosmolar hyperglycemia during glycerol therapy for cerebral edema. Neurology 1976; 26: 89-94
277. Whitefield CL. Isoniazid overdose: report of 40 patients with a critical analysis of treatment and suggestions for prevent. Am Rev Respir Dis 1971; 103: 887
278. Dickson I. Glycosuria and diabetes following INAH therapy. Med J Aust 1962; 1: 325-6
279. Fraser AG, Harrower ADB. Convulsions and hyperglycaemia associated with nalidixic acid [letter]. BMJ 1977; 2; 1518
280. Takasu N, Yamada T, Miura H. Rifampicin-induced early hyperglycaemia in humans. Am Rev Respir Dis 1982; 125: 23-7